January 24, 2013
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company
developing drug candidates for the prevention and treatment of cancer, announces that its Annual General
and Special Meeting (the “Shareholder Meeting”) was held today as scheduled.
At the Shareholder Meeting, Helix received approval of 100% of the votes cast by shareholders present, in
person or by proxy, for the special resolution approving the sale of its Rivex Pharma division to
Pharmascience Inc. (“Pharmascience”) for gross cash proceeds of up to $8.5 million, subject to adjustment
(the “Rivex Transaction”).
Robert Verhagen, Chief Executive Officer, said of the result, “We are pleased that Helix’s shareholders have
provided such a strong endorsement of the Rivex Transaction. The transaction will enable Helix to focus its
management and financial resources on its cancer therapeutics products, including its ongoing clinical trial
with L-DOS47, a drug candidate for treatment of non-small cell lung cancer.” The Rivex Transaction was
initially announced by Helix via news release on December 10, 2012 and remains subject to certain
customary closing conditions. The transaction is expected to close on January 25, 2013.
Shareholders approved the election of William B. White, Robert A. Verhagen, Mario Gobbo, Marek
Orlowski, Slawomir Majewski, John A. Rogers and Slawomir Ludwikowski as directors at the Shareholder
Meeting. Shareholders also approved a special resolution approving an amendment to Helix’s Articles
moving Helix’s registered office to Ontario.
KPMG LLP, Chartered Accountants, were appointed as auditors. However, a significant percentage of
proxies received prior to the Shareholder Meeting withheld from voting on the appointment of auditors. The
board of directors expects to meet with shareholders in the near future to better understand the reasons for
this action, and the board will take appropriate action based on these discussions with shareholders.
At a board meeting held after the Shareholder Meeting, the newly-elected directors considered the structure
of the board and the composition of the board committees. Mr. Gobbo was appointed as Chair of the new
“It has been a privilege to serve as Chair over the last ten months”, said Mr. White. “Now that the business
has stabilized, it is time to work on the next phase of Helix’s development. I look forward to continuing my
work as a director on the board.”
“I thank Bill for his leadership,” said Mr. Gobbo, “and I look forward to working with the board and
management on the development and funding of Helix’s proprietary technologies.”
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. Helix is
actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and its
Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol “HBP”.
Helix BioPharma Corp.
Tel: 905 841-2300
This news release contains certain forward-looking statements and information (collectively, “forwardlooking statements”) within the meaning of applicable Canadian securities laws, including with respect to Helix’s ongoing business and operations following completion of the Rivex Transaction, and the focus on LDOS47 in particular. Forward-looking statements, which may be identified by words including, without limitation, “will”, “may”, “subject”, “expects”, and other similar expressions, are intended to provide information about management’s current plans and expectations regarding future operations.
Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements are more fully described in Helix’s most recent Annual Report, including under the headings “Forward-Looking Statements” and “Risk Factors”, filed with the Canadian Securities Administrators under Helix’s profile on SEDAR at www.sedar.com (together, the “Helix Risk Factors”). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix’s actual results or events to differ materially from the forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix’s management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.